Pathogenesis of inflammatory bowel disease

Problems in General Surgery

Volumn 16, Issue 2, 1999, Pages 1-11

  Stucchi, Arthur F ^a   Becker, James M ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CHEMOKINE; CYTOKINE; LEUKOTRIENE; NITRIC OXIDE; PROSTAGLANDIN;

CROHN DISEASE; ENTERITIS; HUMAN; IDIOPATHIC DISEASE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTION; INTESTINE FUNCTION; INTESTINE INJURY; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; ULCERATIVE COLITIS;

EID: 0032976208     PISSN: 07398328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Hanauer SB. Inflammatory bowel disease. N Eng J Med 1996;334:841-8.
2. Sutherland LR. Clinical course and complications of ulcerative colitis and ulcerative proctitis. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:279-95.
3. Levine DS. Clinical features and complications of Crohn's disease. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:296-316.
4. Roy MA. Inflammatory bowel disease. Surg Clin North Am 1997;77:1419-31.
5. Truelove SC, Wilts LJ. Cortisone in ulcerative colitis: final report of a therapeutic trial. Br J Med 1955;2: 1041-8.
6. Podolsky DK. Inflammatory bowel disease. NE J Med 1991;325:928-37.
7. Geller SA. Pathology of inflammatory bowel disease: a critical appraisal in diagnosis and management. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:336-51.
8. O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. J Parenter Enteral Nutr 1989;13:579-85.
9. MacDermott RP, Sanderson IR, Reinecker H-C. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1998;4:54-67.
10. Admans H, Worwell PJ, Wright R. Diagnosis of Crohn's disease. Dig Dis Sci 1980;25:911-5.
11. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
12. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastro Clinics of NA 1995;24:475-507.
13. Shanahan F. Current concepts of the pathogenesis of inflammatory bowel disease. Irish J Med Sci 1994; 163:544-9.
14. Langman MFS. Epidemiological overview of inflammatory bowel disease. In: Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW, eds. Inflammatory bowel diseases. New York: Churchill Livingstone, 1997:35-9.
15. Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996;31:417-27.
16. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut 1994;35: 696-700.
17. Koutroubakis I, Pena AS. Genetics of inflammatory bowel disease. In: Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW, eds. Inflammatory bowel diseases. New York: Churchill Livingstone, 1997:13-26.
18. Jewell DP. Immunology of inflammatory bowel disease - an update. J Gastroenterol 1995;30(Suppl 8): 78-82.
19. Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
20. Yang H, Rotter JI, Toyoda H, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92:1080-4.
21. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterol 1996;43:381-93.
22. Owen DA, Reid PE. Histochemical alterations of mucin in normal colon, inflammatory bowel disease and colonic adenocarcinoma. Histochemical J 1995; 27:882-9.
23. Playford R, J. Trefoil peptides: what are they and what do they do. J Royal Coll Phys of London 1997;31: 37-41.
24. Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking - a review. Am J Gastroenterol 1998;93:144-9.
25. Silverstein MD, Lashner BA, Hanauer SB. Cigarette smoking and ulcerative colitis: a case-control study. Mayo Clin Proc 1994;69:425-9.
26. Franchesi S, Panza E, LaVecchia C, Parazzini F, Decarli A, Bianchi-Porro G. Nonspecific inflammatory bowel disease and smoking. Am J Epidemiol 1987;125: 445-52.
27. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989;34: 1841-54.
28. Green JT, Rhodes J, Ragunath K, et al. Clinical status of ulcerative colitis in patients who smoke. Am J Gastroenterol 1998;93:1463-7.
29. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 1997;3:230-5.
30. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
31. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-9.
32. Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995;108:132-7.
33. Duchmann R, Kaiser I, Hermann E, Mayet WE, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995;102: 448-55.
34. Chadwick VS, Anderson RP. Inflammatory products of commensal bacteria and gastrointestinal disorders. Dig Dis 1990;8:253-68.
35. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
36. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114: 262-7.
37. Yamada T, Grisham MB. Pathogenesis of tissue injury: Role of reactive metabolites of oxygen and nitrogen. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:133-50.
38. Ehrhardt RO. New insights into the immunopathology of chronic inflammatory bowel disease. Semin Gastroenterol Dis 1996;7:144-50.
39. Brandtzaeg P, Halstensen TS, Kett K, et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989;97:1562-84.
40. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 1993;150:2487-93.
41. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalize with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut 1993;35:650-7.
42. Saxon A, Shanahan F, Lander C, Ganz T, Targan S. A distinct subset of antineutrophil antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-10.
43. Targan SR. New IBD markers: definition of disease heterogeneity. Can J Gastroenterol 1995;9:301-4.
44. Freeman H, Roeck B, Devine D, Carter C. Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Can J Gastroenterol 1997;11:203-7.
45. Toy LS, Mayer L. Basic and clinical overview of the mucosal immune system. Semin Gastrointest Dis 1996;7:2-11.
46. Beagley KW, Elson CO. Cells and cytokines in mucosal immunity and inflammation. Gastroenterol Clin North Am 1992;21:347-66.
47. MacDermott RP. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 1996;31:907-16.
48. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997;112:1493-505.
49. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunology 1995;3:171-4.
50. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-74.
51. Fiocchi C. New concepts of pathogenesis in IBD. In: Sutherland LR, eds. Inflammatory bowel disease: basic research, clinical implications and trends in therapy. Boston: Kluwer Academic, 1994:243-61.
52. Lionetti P, Breese E, Braegger CP, Murch SH, Taylor J, MacDonald TT. T-cell activation can induce either mucosal destruction or adaptation in cultured human fetal small intestine. Gastroenterology 1993;105: 373-81.
53. Selby WS, Janossy G, Bofill M, Jewell DP. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation technique. Gut 1984;25:32-40.
54. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:274-82.
55. Williams N. T cells on the mucosal frontline. Science 1998;280:198-200.
56. Trejdosiewicz LK, Smart CJ, Oakes DJ, et al. Expression of T-cell receptors TcR1 (gamma/delta) and TcR2 (alpha/beta) in the human intestinal mucosa. Immunology 1989;68:7-12.
57. Fukushima K, Masuda T, Ohtani H, et al. Immunohistochemical characterization, distribution, and ultrastructure of lymphocytes bearing T-cell receptor gamma/delta in inflammatory bowel disease. Gastroenterology 1991;101:670-8.
58. Gulwani-Akolkar B, Akolkar PN, McKinley M, Fisher SE, Silver J. Crohn's disease is accompanied by changes in the CD4+, but not CD8+, T cell receptor BV repertoire of lamina propria lymphocytes. Clin Immunol Immunopathol 1995;77:95-106.
59. Elewaut D, DeKeyser F, Cuvelier C, et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1998;33:743-8.
60. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273:G769-G75.
61. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993;69: 77-85.
62. Yamamoto H, Morise K, Kusugami K, et al. Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease. J Gastroenterol 1996;31:525-32.
63. Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharm Exp Ther 1997;280:988-1000.
64. Colletti LM, Kunkel SL, Strieter RM. Cytokines. In: Greenfield LJ, eds. Surgery: scientific principles and practice. Philadelphia: Lippincott, 1993:108-30.
65. Van Dullemen H, Meenan J, Stronkhorst A, Tytgat GN, van Deventer SJ. Mediators of mucosal inflammation: implications for therapy. Scand J Gastroenterol 1997;223:92-8.
66. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9.
67. Kusugami K, Youngman KR, West GA, Fiocchi C. Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis, and controls. Gastroenterology 1989;97:1-9.
68. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
69. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 1996; 110:1683-95.
70. Schreiber S, Heinig T, Panzer U, et al. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995;108:21-33.
71. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998;42:470-6.
72. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatroy role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-44.
73. Autschbach F, Braunstein J, Helmke B, et al. In situ expression of interleukin 10 in noninflamed human gut and in inflammatory bowel disease. Am J Path 1998; 153:121-30.
74. Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 1995;38:831-7.
75. Bussolino F, Breviario F, Tetta C, Aglietta M, Mantovani A, Dejana E. Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest 1986;77:2027-33.
76. Denizot Y, Chaussade S, Nathan N, et al. PAF-acether and acetylhydrolase in stool of patients with Crohn's disease. Dig Dis Sci 1992;37:432-7.
77. Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988;95:1167-72.
78. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Eng J Med 1998;338:436-45.
79. Daig R, Andus T, Aschenbrenner E, Falk W, Scholmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996;38:216-22.
80. Simmonds NJ, Rampton DS. Inflammatory bowel disease - a radical view. Gut 1993;34:865-8.
81. Shanahan F, Bernstein CN. Interleukin 8, neutrophils and acute inflammation. Gastroenterology 1992;103: 341-3.
82. Grisham MB. Oxidants and free radicals in inflammatory bowel diseases. Lancet 1994;344:859-61.
83. Weiss SJ. Tissue destruction by neutrophils. N Eng J Med 1989;320:365-76.
84. Zimmerman BJ, Granger DN. Oxygen free radicals and the gastrointestinal tract: role in ischemia-reperfusion injury. Hepatogasteroenterology 1994; 41:337-42.
85. Conner EM, Brand SJ, Davis JM, Kang DY, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression. Inflamm Bowel Dis 1996;2:133-47.
86. Grisham MB, Yamada T. Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann NY Acad Sci 1992;664:103-15.
87. Buffington GD, Doe WF. Depleted mucosal antioxidant defenses in inflammatory bowel disease. Free Radical Biol Med 1995;19:911-18.
88. Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996;41:2078-86.
89. Unno N, Wang H, Menconi MJ, et al. Inhibition of inducible nitric oxide synthase ameliorates endotoxin-induced gut mucosal barrier dysfunction in rats. Gastroenterology 1997;113:1246-57.
90. Kimura H, Miura S, Shigematsu T, et al. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig Dis Sci 1997;42:1047-54.
91. Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991;36:174-8.
92. Salim AS. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J Lab Clin Med 1992; 119:710-7.